155 related articles for article (PubMed ID: 24637269)
1. Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.
Majmudar PA; Clinch TE
Cornea; 2014 May; 33(5):457-62. PubMed ID: 24637269
[TBL] [Abstract][Full Text] [Related]
2. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients.
Nielsen SA; McDonald MB; Majmudar PA
Clin Ophthalmol; 2013; 7():149-56. PubMed ID: 23355771
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
4. Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
Parekh JG; Newsom TH; Nielsen S
J Cataract Refract Surg; 2012 Oct; 38(10):1864-7. PubMed ID: 22999608
[No Abstract] [Full Text] [Related]
5. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Yoshida J; Kim A; Pratzer KA; Stark WJ
J Cataract Refract Surg; 2010 Sep; 36(9):1499-502. PubMed ID: 20692561
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
7. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.
Schechter BA; Parekh JG; Trattler W
J Ocul Pharmacol Ther; 2015 Mar; 31(2):114-21. PubMed ID: 25409447
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.
Garg P; Mathur U; Sony P; Tandon R; Morris TW; Comstock TL
Asia Pac J Ophthalmol (Phila); 2015; 4(3):140-5. PubMed ID: 26065499
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
Comstock TL; Paterno MR; Decory HH; Usner DW
Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472
[TBL] [Abstract][Full Text] [Related]
10. Besifloxacin ophthalmic suspension 0.6%.
Carter NJ; Scott LJ
Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
[TBL] [Abstract][Full Text] [Related]
11. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
Malhotra R; Ackerman S; Gearinger LS; Morris TW; Allaire C
Drugs R D; 2013 Dec; 13(4):243-52. PubMed ID: 24142473
[TBL] [Abstract][Full Text] [Related]
12. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
13. Incidence of corneal infections after laser in situ keratomileusis and surface ablation when moxifloxacin and tobramycin are used as postoperative treatment.
Ortega-Usobiaga J; Llovet-Osuna F; Djodeyre MR; Llovet-Rausell A; Beltran J; Baviera J
J Cataract Refract Surg; 2015 Jun; 41(6):1210-6. PubMed ID: 26096523
[TBL] [Abstract][Full Text] [Related]
14. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
15. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
O'Brien TP
Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
17. The role of besifloxacin in the treatment of bacterial conjunctivitis.
Mahvan TD; Hornecker JR; Buckley WA; Clark S
Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.
Bucci FA; Evans RE; Amico LM; Morris TW; Fluet AT; Sanfilippo CM; DeCory HH; Comstock TL
Clin Ophthalmol; 2015; 9():843-52. PubMed ID: 25999691
[TBL] [Abstract][Full Text] [Related]
19. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK.
Durrie DS; Trattler W
J Ocul Pharmacol Ther; 2005 Jun; 21(3):236-41. PubMed ID: 15969641
[TBL] [Abstract][Full Text] [Related]
20. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
